-
Je něco špatně v tomto záznamu ?
ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients
A. Mareckova, J. Malcikova, N. Tom, K. Pal, L. Radova, D. Salek, A. Janikova, M. Moulis, J. Smardova, L. Kren, J. Mayer, M. Trbusek,
Leukemia & lymphoma.
2019 ;
60 (6) :
1420-1428.
[pub] 20190110
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Perzistentní odkaz
https://www.medvik.cz/link/bmc20025841
- MeSH
- ATM protein genetika metabolismus MeSH
- genetická predispozice k nemoci * MeSH
- genetické asociační studie MeSH
- lidé MeSH
- lymfom z plášťových buněk genetika mortalita patologie terapie MeSH
- mutace * MeSH
- nádorové biomarkery MeSH
- nádorový supresorový protein p53 genetika metabolismus MeSH
- prognóza MeSH
- sekvenční delece MeSH
- transkripční faktory SOXC genetika metabolismus MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Mantle cell lymphoma (MCL) is characterized by the hallmark t(11;14)(q13;q32) translocation, leading to cyclin D1 over-expression. Additionally, disrupting the DNA damage response pathway through ATM or TP53 defects plays an important role in MCL pathogenesis. Using deep next-generation sequencing we analyzed the mutual composition of ATM and TP53 mutations in 72 MCL patients, and assessed their impact on progression-free survival (PFS) and overall survival (OS). Mutated ATM and TP53 alleles were found in 51% (37/72) and 22% (16/72) of the cases examined, respectively, with only three patients harboring mutations in both genes. Only a mutated TP53 gene was associated with the significantly reduced PFS and OS and the same output was observed when ATM and TP53 defective groups included also sole deletions 11q and 17p, respectively. Determining the exact ATM/p53 pathway dysfunction may influence the selection of MCL patients for innovative therapies based on the targeted inhibition of selected proteins.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025841
- 003
- CZ-PrNML
- 005
- 20201222155504.0
- 007
- ta
- 008
- 201125s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/10428194.2018.1542144 $2 doi
- 035 __
- $a (PubMed)30626249
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Mareckova, Andrea $u a Department of Internal Medicine - Hematology and Oncology , University Hospital Brno and Faculty of Medicine, Masaryk University , Brno , Czech Republic.
- 245 10
- $a ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients / $c A. Mareckova, J. Malcikova, N. Tom, K. Pal, L. Radova, D. Salek, A. Janikova, M. Moulis, J. Smardova, L. Kren, J. Mayer, M. Trbusek,
- 520 9_
- $a Mantle cell lymphoma (MCL) is characterized by the hallmark t(11;14)(q13;q32) translocation, leading to cyclin D1 over-expression. Additionally, disrupting the DNA damage response pathway through ATM or TP53 defects plays an important role in MCL pathogenesis. Using deep next-generation sequencing we analyzed the mutual composition of ATM and TP53 mutations in 72 MCL patients, and assessed their impact on progression-free survival (PFS) and overall survival (OS). Mutated ATM and TP53 alleles were found in 51% (37/72) and 22% (16/72) of the cases examined, respectively, with only three patients harboring mutations in both genes. Only a mutated TP53 gene was associated with the significantly reduced PFS and OS and the same output was observed when ATM and TP53 defective groups included also sole deletions 11q and 17p, respectively. Determining the exact ATM/p53 pathway dysfunction may influence the selection of MCL patients for innovative therapies based on the targeted inhibition of selected proteins.
- 650 _2
- $a ATM protein $x genetika $x metabolismus $7 D064007
- 650 _2
- $a nádorové biomarkery $7 D014408
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a genetické asociační studie $7 D056726
- 650 12
- $a genetická predispozice k nemoci $7 D020022
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lymfom z plášťových buněk $x genetika $x mortalita $x patologie $x terapie $7 D020522
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a mutace $7 D009154
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a transkripční faktory SOXC $x genetika $x metabolismus $7 D055751
- 650 _2
- $a sekvenční delece $7 D017384
- 650 _2
- $a nádorový supresorový protein p53 $x genetika $x metabolismus $7 D016159
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Malcikova, Jitka $u a Department of Internal Medicine - Hematology and Oncology , University Hospital Brno and Faculty of Medicine, Masaryk University , Brno , Czech Republic.
- 700 1_
- $a Tom, Nikola $u b Central European Institute of Technology (CEITEC), Center of Molecular Medicine, Masaryk University , Brno , Czech Republic.
- 700 1_
- $a Pal, Karol $u b Central European Institute of Technology (CEITEC), Center of Molecular Medicine, Masaryk University , Brno , Czech Republic.
- 700 1_
- $a Radova, Lenka $u b Central European Institute of Technology (CEITEC), Center of Molecular Medicine, Masaryk University , Brno , Czech Republic.
- 700 1_
- $a Salek, David $u a Department of Internal Medicine - Hematology and Oncology , University Hospital Brno and Faculty of Medicine, Masaryk University , Brno , Czech Republic.
- 700 1_
- $a Janikova, Andrea $u a Department of Internal Medicine - Hematology and Oncology , University Hospital Brno and Faculty of Medicine, Masaryk University , Brno , Czech Republic.
- 700 1_
- $a Moulis, Mojmir $u c Department of Pathology, University Hospital Brno and Faculty of Medicine , Masaryk University , Brno , Czech Republic.
- 700 1_
- $a Smardova, Jana $u c Department of Pathology, University Hospital Brno and Faculty of Medicine , Masaryk University , Brno , Czech Republic.
- 700 1_
- $a Kren, Leos $u c Department of Pathology, University Hospital Brno and Faculty of Medicine , Masaryk University , Brno , Czech Republic.
- 700 1_
- $a Mayer, Jiri $u a Department of Internal Medicine - Hematology and Oncology , University Hospital Brno and Faculty of Medicine, Masaryk University , Brno , Czech Republic.
- 700 1_
- $a Trbusek, Martin $u a Department of Internal Medicine - Hematology and Oncology , University Hospital Brno and Faculty of Medicine, Masaryk University , Brno , Czech Republic.
- 773 0_
- $w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 60, č. 6 (2019), s. 1420-1428
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30626249 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222155500 $b ABA008
- 999 __
- $a ok $b bmc $g 1599986 $s 1116527
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 60 $c 6 $d 1420-1428 $e 20190110 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140
- LZP __
- $a Pubmed-20201125
